Patient Mobility for Elective Secondary Health Care Services in Response to Patient Choice Policies: A Systematic Review

Ajay Aggarwal(King's College London), Jan van der Meulen(London School of Hygiene & Tropical Medicine), Richard Sullivan(Precision Spine (United States)), Malcolm D. Mason(Royal Marsden Hospital), Daniel Lewis(The Huntington Library, Art Museum, and Botanical Gardens)
Medical Care Research and Review
June 28, 2016
10.1177/1077558716654631
Cited by 98

Related Papers

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study
|The Lancet Oncology|2020|1.9k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
The Lancet Commission on diagnostics: transforming access to diagnostics
|The Lancet|2021|442
Age, chronic disease, sepsis, organ system failure, and mortality in a medical intensive care unit
|Critical Care Medicine|1990|368